SEC Tracker
Get the app

Naploy NPLY

Naploy Q1 FY25: revenue $581; diluted EPS $0.00

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q

Key figures from this report

These are the numbers Naploy reported for Q1 FY25, the quarter ended Oct 31, 2024, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$581No year-earlier figure tagged10-Q income statement, on EDGAR
  2. Net income−$10KNo year-earlier figure tagged10-Q income statement, on EDGAR
  3. Diluted EPS$0.00No year-earlier figure tagged10-Q income statement, on EDGAR
  4. Cash and cash equivalents$28KNo year-earlier figure tagged10-Q balance sheet, on EDGAR
  5. Cash from operations−$6KNo year-earlier figure tagged10-Q cash flow statement, on EDGAR

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Naploy files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 8000 and related industry codes: the same peer list as the financial tables.

  1. Alps Group ALPS
  2. American Oncology Network AONC
  3. Agape ATP ATPC public float $5M, Dec 31, 2025
  4. Anew Health AVG
  5. Better Therapeutics BTTX